Alessandro Morabito
Naples, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 85 publications
Corrigendum to 'Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational study' [Cancer Treat Res Commun. 2026:47:101143].
Journal: Cancer treatment and research communications
Published: August 25, 2026
SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 27, 2026
Response to Letter Re: Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the ISTOP study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 10, 2026
MiR-23c Regulates the Resistance to Gefitinib in EGFR Mutant Non-Small-Cell Lung Cancer Cells.
Journal: Cells
Published: March 30, 2026
Imaging and AI in tertiary prevention of lung cancer: Narrative review and clinical perspectives.
Journal: Multidisciplinary respiratory medicine
Published: February 02, 2026
Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 25, 2025
Chemoimmunotherapy Combinations in Elderly Patients with Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression < 50%: Results from an Italian Real-World Study.
Journal: Journal of clinical medicine
Published: November 23, 2025
Validity and responsiveness of patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) among Italian lung cancer patients.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 17, 2025
Staphylococci: What Has Changed in the Antibiotic Resistance Profile in the Last Decade-Analysis of Strains Isolated from Hospitalised Patients.
Journal: Pathogens (Basel, Switzerland)
Published: November 10, 2025
An ISO 31000-Based Risk Matrix for Risk Management in Anticancer Drug Prescription, Compounding, and Administration for Lung Cancer Patients Treated in a Day Hospital Setting.
Journal: Risk management and healthcare policy
Published: October 02, 2025
Germline Findings From Tumor-Only Comprehensive Genomic Profiling in the RATIONAL Study: A Missed Opportunity?
Journal: JCO precision oncology
Published: September 10, 2025
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: August 17, 2025
Last Updated: 09/26/2026